Details for: XGEVA
Company: AMGEN CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02368153 | XGEVA | DENOSUMAB | 120 MG / 1.7 ML | SOLUTION | SUBCUTANEOUS |
Summary Reports
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness
Summary Safety Review - PROLIA (denosumab) - Cardiovascular events
Summary Safety Review - PROLIA (denosumab) - Risk of Malignancy (Cancer)
Regulatory Decision Summary
Summary Safety Review - Denosumab (Prolia and Xgeva) - Hearing loss and deafness
Summary Safety Review - PROLIA (denosumab) - Cardiovascular events
Summary Safety Review - PROLIA (denosumab) - Risk of Malignancy (Cancer)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.